Choose your preferred way to stay informed of new case launches and settlement deadlines
The filed complaint alleges that Keros Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose that: Keros issued a press release on December 12, 2024, "announc[ing] that it has voluntarily halted dosing in the 3.0 mg/kg and 4.5 mg/kg treatment arms in the ongoing TROPOS trial, a Phase 2 clinical trial of cibotercept (KER-012) in combination with background therapy in patients with pulmonary arterial hypertension ("PAH"), based on a safety review due to the unanticipated observation of pericardial effusion adverse events in the trial." Following this news, Keros's stock price fell sharply during intraday trading on the same day.
In order to be eligible to join the KROS class action lawsuit, you must have incurred a loss on shares of Keros Therapeutics, Inc. purchased during the class period listed above.
TOP
